Eppendorf_eBook_Centrifuge_May25
  Editorial
 SUPREME COURT’S INTERVENTION NEEDED   
 Wednesday, May 14, 2025 
 Availability of drugs for rare diseases or orphan diseases at reasonably affordable prices has been a major issue the country, for that matter the entire world, has been facing for a long time now. 
  Past Editorial...  
TODAY'S NEWS
12:00  [IST]GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma
11:00  [IST]Monash University and Peninsula Health develop AI method to improve dementia diagnosis
10:00  [IST]Taiwan FDA approves Chugai Pharma’s PiaSky for subcutaneous treatment of patients with paroxysmal nocturnal hemoglobinuria
09:00  [IST]JSAI demands Odisha govt to look into growing kidney cases and patient deaths
more news >>
TOP NEWS
08:00  [IST]Pharmaceuticals exports grew 2.37 per cent in April 2025
08:00  [IST]Organisers of 74th IPC buoyant to attract over 12,000 delegates driven by its theme ‘AI & Technology in Pharma’
08:00  [IST]NABL introduces dedicated software to help labs adopt QR Code and ULR authentication system
08:00  [IST]Kerala poised to become global leader in medical devices and ancillary industries in next 5 years: Dr Satheesh Kumar
08:00  [IST]DGFT amends import norms for Di-octyl phthalate to enhance export efficiency
08:00  [IST]Pharma sector reported steady growth of 10% annually in last five years: Centre
more news >>
YESTERDAY'S NEWS
18:00  [IST]Neutron Therapeutics & Helsinki University Hospital treat first head and neck cancer patients using accelerator-based boron neutron capture therapy
17:15  [IST]Cytecare highlights at vital role of Oncoanesthesia CANCON 2025
17:00  [IST]Acadia Pharma gets favourable ruling from Delaware District Court in Nuplazid formulation patent litigation
16:45  [IST]Venus Remedies joins United Nations Global Compact, reinforcing commitment to sustainable global healthcare
16:00  [IST]Bristol Myers Squibb gets European nod for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable, high-risk NSCLC with PD-L1 expression =1%
14:40  [IST]Nearly 30% of India’s adult population under the age of 40 is affected by hypertension or prehypertension, Dr Preetha Reddy
more news >>
INTERVIEW  
All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?
 
 
 
   
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
Avians_2025
API_China_2025
CPHISEA25
worldadc-asia_25
ProPak_Asia_2025
CPHI_PMEC_China_2025
Pharmatech_Lab_Expo2025
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram